1st July 2022. PharmaKure announce a ground breaking study of a blood biomarker trial using their proprietary ALZmetrix® assay with Alzheimer's disease patients.

March 26th 2021. PharmaKure is delighted to announce the completion of the acquisition of the CynapseDx assays for oligomeric proteins. This is the final step that secured invesment of £4 million from a private investor and the UK Future Fund to finance clinical trials on their leading drug candidate PK051 for Alzheimer's disease.

PharmaKure Limited and CynapseDx Limited have signed a letter of intent for a commercial relationship between the two companies which could result in a collaboration or acquisition to secure funding.